Skip to main content
Caplight Logo









Ensocell

Ensocell

Private
CambridgeHealthcare & Life Scienceshttps://ensocell.com

Last Round

Seed

May 7, 2024

Total Funding Raised

$16.3M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Ensocell operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Seed round in May 2024.

Ensocell is a biotechnology company that utilizes single-cell genomics and AI-based computational tools to discover precision biologics for autoimmune, inflammatory, and fibrotic diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Ensocell Comparables

Compare Ensocell with similar companies based on industry and business-model similarity.

Ensocell comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Scailyte AG
80%
Variant Bio
78%
Atlas Discovery
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Ensocell Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 7, 2024
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Ensocell Investors

Notable investors and investment history

Ensocell investors
InvestorRounds
OMX VenturesSeed
Sofinnova PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 30, 2026

    Grew 25% quarter-over-quarter, from 20 to 25 employees.

  • Jul 20, 2026

    Grew 21% QoQ, from 19 to 23 employees.

Book a demo to see all signals

For institutional investors. Book with your work email.

Ensocell Filings

Explore SEC and related filing metadata, where available.

Ensocell filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Ensocell's valuation, stock price, and market status.

Is Ensocell a public or private company?

Ensocell is a private company.

What is the current stock price of Ensocell?

Ensocell is a private company, so its shares have no public market price. Caplight tracks Ensocell's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Ensocell worth (valuation)?

Valuation information for Ensocell is not publicly available.

Can I buy Ensocell stock?

Ensocell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Ensocell's last funding round?

Ensocell's most recent funding round was Seed on May 7, 2024.

Who are the main investors in Ensocell?

Key investors in Ensocell include OMX Ventures, Sofinnova Partners.

Will Ensocell IPO soon?

No public IPO plans have been announced for Ensocell.

How can I track Ensocell secondary market activity?

Caplight tracks bids, offers, and trades in Ensocell's shares on secondary markets.

Firmographic Details

HeadquartersCambridge
Employee Range23
Year Founded2023
Last FundingMay 7, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?